Efektivitas Penambahan Krim Tretinoin 0,025% pada Krim Desoksimetason terhadap Repigmentasi Kulit Pasien Vitiligo
DOI:
https://doi.org/10.55175/cdk.v47i5.374Keywords:
Kortikosteroid, tretinoin, vitiligoAbstract
Pendahuluan: Vitíligo adalah kelainan didapat yang ditandai dengan bercak depigmentasi berbatas tegas akibat hilangnya melanosit
fungsional. Kortikosteroid topikal masih merupakan terapi andalan. Tretinoin diduga juga mempunyai efek repigmentasi pada pasien vitiligo. Tujuan: Untuk membuktikan efektivitas penambahan tretinoin 0,025% pada krim desoksimetason terhadap repigmentasi vitiligo. Metode: Uji klinis dengan kelompok kontrol pre- dan post test, pada pasien vitiligo di Poliklinik Kulit dan Kelamin RS Dr. Moewardi Surakarta antara Januari dan April 2019. Kelompok kontrol menerima desoksimetason saja, sedangkan kelompok perlakuan mendapat tretinoin 0,025% dikombinasi dengan desoksimetason. Setiap lesi difoto dengan menyertakan penggaris sebagai skala untuk memudahkan penghitungan dengan program komputer, diproses mengunakan program Adobe photoshop CS5 extended version 12.0 x32, 2010 dan Coreldraw x7 version 17.0.0.491 2014 Corel corporation. Analisis statistik menggunakan uji Mann Whitney dan Wilcoxon, nilai p <0,05 dianggap signifikan. Hasil: Hasil analisis gambar menunjukkan penurunan luas lesi signifikan pada kelompok studi dibandingkan kelompok kontrol pada bulan ke-3 setelah terapi (p = 0,000). Simpulan: Kombinasi tretinoin 0,025% dan krim desoksimetason lebih efektif daripada terapi tunggal dalam mengobati vitiligo.
Introduction: Various types of therapeutic modalities are used for repigmentation in vitiligo lesions and to stabilize the depigmentation process. Objective: To prove the efficacy of tretinoin 0.025% addition to desoximetasone cream in repigmentation process. Methods: Clinical trial with pre- and posttest control group design, conducted in vitiligo patients in Dermatovenereology Departement of Dr. Moewardi General Hospital between January and April 2019. Control group received desoximethasone only and study group received tretinoin 0.025% combined with desoximethasone. Each lesion was photographed with a ruler scale to facilitate calculations with computer programs Adobe Photoshop CS5 extended version 12.0 x32, 2010 and Coreldraw x7 version 17.0.0.491 2014 Corel Corp. Statistical analysis used Mann Whitney and Wilcoxon test. Result: Image analysis revealed a significant decrease of lesion area in the study group (p=0.000). Conclusion: Combination of tretinoin and desoximetasone cream is more effective than single therapy in treating vitiligo.
Downloads
References
Ghafourian E, Ghafourian S, Sadeghifard N, Mohebi R, Shokoohini Y, Nezamoleslami S, et al. Vitiligo: Symptoms, pathogenesis and treatment. Internat J Immunopathol Pharmacol. 2014;27:485-9.
Taieb A, Picardo M. Vitiligo. N Engl J Med. 2009;360:160-9.
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008;9:345-59.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology and work-up. J Am Acad Dermatol. 2011;65:473-86.
Nurhayati D. Uji banding efektivitas kalsipotriol topikal, suction blister grafting dan kombinasi keduanya pada terapi repigmentasi lesi vitiligo stabil. Media Medika Indones. 2012;46:114-21.
Ortonne JP, Passeron T. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012.
Lannella G, Greco A, Didona D, Didona B, Granata G, Manno A, et al. Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2016;15(4):335-43.
Garg BJ, Saraswat A, Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprosy. 2010;76:231-7.
Jackson SM Jr, Nesbitt LT. Glucocorticosteroids. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd Ed. London: Elsevier Saunders; 2012.
Kwon HB, Choi Y, Kim HJ, Lee AY. The therapeutic effects of topical tretinoin and corticosteroid combination for vitiligo: A placebo-controlled, paired-comparison, Left-Right Study. J Drugs Dermatol. 2013;12:63-7.
Behrangi E, Rasi A, Jannati F, Jannati P, Beigmohammadi F, Azizian Z. Comparative study of the therapeutic effects of topical mometasone furoate 0.1% plus tretinoin 0.05% and topical mometasone furoate 0.1% plus eucerin in the treatment of vitiligo. J Skin Stem Cell. 2015;2:1-4.
Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the published work. J Dermatol. 2011;38:419-31.
Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51:1206-12.
Rahmayanti ND. Studi retrospektif : Profil pasien baru vitiligo. Berk Ilmu Kes Kulit dan Kelamin. 2016;28(2):52-8.
Diana R, Mulianto N. Profil pasien vitiligo di poliklinik kulit dan kelamin RSUD dr. Moewardi Surakarta periode Januari 2013 - Desember 2016. Surakarta. Laporan Penelitian. 2017 .p. 1-14.
Le Poole IC, Das PK, Westerhof W. Review of the etiopathomechanism of vitiligo: A convergence theory. Experimental Dermatol. 1993;2:145-53.
Alghamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol. 2012;26(12):1463-71.
Sheth VM, Rithe R, Pandya AG, Chandrakasan A. A pilot study to determine vitiligo target size using a computer-based image analysis program. J Am Acad Dermatol. 2015;73:342-5.
Nugroho H, Fadzil MHA, Shamsudin N, Hussein SH. Computerised image analysis of vitiligo lesion: Evaluation using manually defined lesion areas. Skin Res Technol. 2012;0:1-6.
Fadzil MHA, Norashikin S, Suraiy H, Nugroho H. Independent component analysis for assessing therapeutic response in vitiligo skin disorder. J Med Engineer Technol. 2009;33:101-9.
De Oliveira MR. Vitamin A and retinoids as mitochondrial toxicants. Oxidative Medicine and Cellular Longevity [Internet]. 2015:1-14. Available from: https://www.hindawi.com/journals/omcl/2015/140267/
Xiao S, Jin H, Korn K, Liu SM, Oukka M, dkk. Tretinoin 0.025% increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF--driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol. 2008;181:2277–84.
Dhamayanti ME, Kusumawardani A. Perbandingan efektivitas terapi kombinasi tretinoin topikal 0.025% dengan kortikosteroid topikal dan vaselin album dengan kortikosteroid topikal pada pasien vitiligo. Laporan Penelitian. 2017 .p. 1-9.
Kuenzli S, Sorg O, Saurat JH. Side effects and pitfalls in retinoid therapy. Department of Dermatology. Geneva University Hospital. Geneva, Switzerland. Researchgate. 2007:1-25.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
